Replies to post #3880 on Biotech Values

[DewDiligence]

>> I think Topol's comments were a little over the top and not entirely fair. They had fda permission to take an interim look and took a statistical hit for it. <<

I’ve just been arguing this point over on the AGIX board. Yes, the interim look per se was sanctioned by the FDA. But that doesn’t absolve the company and the clinicians from criticism for sloppiness, subjectivity in excluding data, reporting essentially meaningless p-values to investors, and rushing the analyses in order to meet the company’s promise of giving investors an update during Q3.

>> Full data set in Dec, we'll see. <<

This phase-2b trial may be too screwed up for any information of consequence to be gleaned from it. However, if the drug works and the phase-*3* trial in progress continues as planned, the setback from the current problems may be inconsequential in the overall scheme of things.

[DewDiligence]

>> Even #2, assuming a need for a 2nd and larger pivotal trial and multi year delay would be considered a negative outcome. >>

As mentioned in the previous post, I think it’s already highly likely that the phase-2b won’t be eligible for consideration as a pivotal.